Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.56 USD
-0.06 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $64.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Alpine Immune Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 59 | 30 | 23 | 9 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 59 | 30 | 23 | 9 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 103 | 88 | 73 | 38 | 45 |
Income After Depreciation & Amortization | -44 | -58 | -50 | -29 | -44 |
Non-Operating Income | 12 | 3 | 0 | 2 | 2 |
Interest Expense | 0 | 0 | 1 | 1 | 0 |
Pretax Income | -32 | -55 | -50 | -28 | -42 |
Income Taxes | 0 | 2 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -32 | -58 | -50 | -28 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -32 | -58 | -50 | -28 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -58 | -48 | -28 | -42 |
Depreciation & Amortization (Cash Flow) | -7 | 0 | 2 | 1 | 2 |
Income After Depreciation & Amortization | -44 | -58 | -50 | -29 | -44 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 50.00 | 33.44 | 25.48 | 20.83 | 18.36 |
Diluted EPS Before Non-Recurring Items | -0.64 | -1.73 | -1.98 | -1.34 | -2.28 |
Diluted Net EPS (GAAP) | -0.64 | -1.73 | -1.98 | -1.34 | -2.28 |
Fiscal Year end for Alpine Immune Sciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 30.85 | 10.04 | 8.59 | 9.39 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 30.85 | 10.04 | 8.59 | 9.39 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 29.30 | 24.59 | 24.25 | 24.98 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.55 | -14.55 | -15.66 | -15.59 |
Non-Operating Income | NA | 4.52 | 2.83 | 2.53 | 2.40 |
Interest Expense | NA | 0.00 | 0.00 | 0.03 | 0.07 |
Pretax Income | NA | 6.06 | -11.72 | -13.16 | -13.27 |
Income Taxes | NA | 0.10 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 5.96 | -11.72 | -13.16 | -13.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 5.96 | -11.72 | -13.16 | -13.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 39.73 | 49.22 | 48.05 | 47.57 |
Diluted EPS Before Non-Recurring Items | NA | 0.15 | -0.24 | -0.27 | -0.28 |
Diluted Net EPS (GAAP) | NA | 0.15 | -0.24 | -0.27 | -0.28 |